- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02749227
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors (PASSILCORT)
Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Neuroendocrine Unit and Pituitary Center, Columbia University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- Adults (males and females) with a diagnosis of a clinically nonfunctioning pituitary tumor of the silent corticotroph tumor type (i.e., positive adrenocorticotropin (ACTH) staining on immunohistochemical staining of the pituitary tumor obtained at surgery)
- Plasma POMC level > upper limit of normal
- Prior pituitary tumor surgery with residual or recurrent pituitary tumor visible on MRI scan that is ≥ 5 mm from the optic chiasm.
- Surgical resection of the pituitary adenoma must have occurred two or more months prior to enrollment
- If patients have undergone pituitary radiotherapy they must have completed their course of radiotherapy at least 2 months prior to study screening
- No prior somatostatin analog therapy
- No concurrent use of dopamine agonist therapy
- No active malignancy
- Stable pituitary hormone supplements (x 2 months) prior to baseline visit
- Sign and date an informed consent document indicating that the subject has been informed of and agrees to all pertinent aspects of the trial
Exclusion criteria:
Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study:
- Patients with Cushing's disease (biochemical evidence of hypercortisolism)
- Patients with compression of the optic chiasm causing any visual field defect that requires surgical intervention
- Diabetic patients with poor glycemic control as evidenced by HbA1c >8%
- Patients who are hypothyroid or adrenally insufficient and not on adequate replacement therapy
- Patients with symptomatic cholelithiasis and acute or chronic pancreatitis
- Patients with risk factors for torsade de pointes, i.e., patients with a baseline QTcF (Fridericia's Correction Formula value) >450 ms in males, and >460 ms in females
- Hypokalaemia, hypomagnesaemia, uncontrolled hypothyroidism, family history of long QT syndrome or concomitant medications with known risk of Torsades de pointes (TdP). Drugs with possible risk of TdP should be avoided whenever feasible
- Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute myocardial infarction (MI) less than one year prior to study entry or clinically significant impairment in cardiovascular function
- Concomitant disease(s) that could prolong the QT interval such as autonomic neuropathy (caused by diabetes or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
- Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 2.0 X upper limit of normal (ULN), serum bilirubin >2.0 X ULN
- Presence of Hepatitis B surface antigen (HbsAg) or Hepatitis C antibody test (anti-HCV)
- Patients with serum creatinine >2.0 X ULN
- Patients with white blood cell (WBC) count <3 X 109/L; Hb 90% < lower limit of normal (LLN); platelet (PLT) count <100 X 109/L
- Patients with the presence of active or suspected acute or chronic uncontrolled infection
- Patients who have undergone major surgery/surgical therapy for any cause within 4 weeks prior screening
- Patients with abnormal coagulation (PT and/or activated partial thromboplastin time (APTT) elevated by 30% above normal limits) or patients receiving anticoagulants that affect PT (prothrombin time) or APTT (activated partial thromboplastin time)
- History of syncope or family history of idiopathic sudden death
- History of immunocompromise, including a positive HIV test result (ELISA and Western blot)
- Sexually active males unless they use a condom during intercourse while taking drug and for 3 months following last dose of pasireotide and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and 3 months following last dose of pasireotide. Highly effective contraception methods include:
- Total abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
- Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject
Combination of any two of the following (a+b or a+c, or b+c):
- Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS)
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
- In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
- Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pasireotide LAR Therapy
Subjects will receive Pasireotide LAR monthly.
Safety labs and Pituitary MRI will be performed.
|
Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use. The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Plasma Proopiomelanocortin (POMC) Levels
Time Frame: Baseline, 12 months
|
This is to measure the effect of Pasireotide LAR (long-acting release) treatment.
|
Baseline, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pituitary Tumor Volume
Time Frame: Baseline, 12 months
|
This is to measure the effect of Pasireotide LAR (long-acting release) treatment.
|
Baseline, 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms
- Pituitary Neoplasms
- Pituitary Diseases
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Pasireotide
Other Study ID Numbers
- AAAQ6255
- CSOM230GUS44T (Other Identifier: Novartis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pituitary Tumor
-
Göteborg UniversityUnknownSurgery | Pituitary Tumor BenignSweden
-
Emory UniversityCompletedAcromegaly | Nonfunctioning Pituitary TumorUnited States
-
Rutgers, The State University of New JerseyTerminated
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingPituitary | Pituitary Tumor | Pituitary Cancer | Pituitary CarcinomaUnited States
-
Neuromed IRCCSRecruitingHyperparathyroidism | Solid Tumor | Pituitary Tumor | Endocrine Neoplasia | Familial Tumor SyndromeItaly
-
Memorial Sloan Kettering Cancer CenterEvergreen Theragnostics; Recordati Pharmaceutical companyRecruitingProlactin-Producing Pituitary TumorUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingPituitary TumorsChina
-
Ohio State UniversityTerminatedPituitary Tumor | Prolactinoma | Prolactin-Producing Pituitary Tumor | Prolactinoma Macroadenoma | Prolactinoma MicroadenomaUnited States
-
Seoul National University HospitalRecruitingPituitary Adenoma | Pituitary Tumor | Prolactinoma | Recurrence TumorKorea, Republic of
-
EndocyteCompletedPituitary TumorsUnited States
Clinical Trials on Pasireotide LAR
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Novartis PharmaceuticalsCompletedCushing's DiseaseItaly, Belgium, Japan, Germany, United Kingdom, Thailand, Spain, France, Netherlands, Turkey, Israel, China, United States, Canada, India, Argentina, Brazil, Peru, Poland, Russian Federation
-
Novartis PharmaceuticalsCompletedNeuroendocrine Carcinoma of the Lung and ThymusItaly, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
-
Novartis PharmaceuticalsCompleted
-
Patrick Y. Wen, MDMemorial Sloan Kettering Cancer Center; Massachusetts General Hospital; Northwestern... and other collaboratorsCompleted
-
Novartis PharmaceuticalsTerminatedIslet Cell TumorFrance, Spain, United Kingdom, Belgium, Hungary, Turkey, Canada, Argentina, Sweden, Italy, Thailand, Germany, Netherlands, Brazil, Australia, Japan, United States, Denmark, New Zealand
-
Novartis PharmaceuticalsCompletedDose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)Neuroendocrine TumorsUnited States
-
University of PennsylvaniaTerminatedGonadotroph AdenomasUnited States
-
Novartis PharmaceuticalsTerminatedPituitary Neoplasm | Pancreatic Neoplasm | Ectopic ACTH Syndrome | Nelson SyndromeGermany, Italy, Australia, Russian Federation, Spain, Thailand, France, Canada, Brazil, United States, Argentina, Mexico
-
Mayo ClinicCompletedAutosomal Dominant Polycystic Kidney Disease | Polycystic Liver Disease | Autosomal Dominant Polycystic Liver Disease | Somatostatin AnalogsUnited States